Tatva Chintan Pharma Chem IPO subscription status day 1: FULLY SUBSCRIBED within hours of opening-check all key details
Tatva Chintan Pharma Chem Ltd IPO opened today July 16, 2021 and will close on Tuesday (20 July).
Tatva Chintan Pharma Chem Ltd IPO received massive response on its opening day as the Initial Public offering was fully subscribed within hours of opening on Friday, July 16, 2021. As per the NSE consolidated bid details, Retail Individual Investors(RIIs) portion was subscribed whooping 2.65 times within hours as a specialty chemical firm received 43,29,208 bids as against 16,30,941 reserved for them. Similarly, overall issue was subscribed 1.34 times as against 32,61,882 shares offerings, Tatva Chintan Pharma Chem Ltd IPO recived 43,78,842 bids.
See Zee Business Live TV Streaming Below:
Tatva Chintan Pharma Chem Ltd IPO will close on Tuesday (20 July). Retail investors who wish to invest in this issue are required to make payments through UPI mode. All other category of investors shall mandatorily use only Application Supported by Blocked Amount (ASBA) facility for making payments.
Tatva Chintan Pharma Chem Ltd IPO Key Details
Symbol - TATVA
Issue Period - 16 July 2021 to 20 July 2021
Post issue Modification Period – 22 July 2021 between 10am and 11 am
Cut-off time for UPI Mandate Confirmation – 22 July 2021 up to 12 pm
Issue Size - Initial Public offer of equity shares aggregating up to Rs 500 cr comprising a fresh Issue of up to Rs 225 cr and an Offer for Sale (OFS) of up to Rs 275 crore
Issue Type – 100 per cent Book Building
Price Range – Rs 1073 to Rs 1083
Face Value - Rs 10
Tick Size - Re 1
Bid Lot 13 equity shares and in multiples thereof
Minimum Order Quantity - 13 equity shares
Maximum Subscription Amount for Retail Investor - Rs 200,000
IPO Market Timings – 10 am to 5 pm
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.